Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H1 2018

  • ID: 4479902
  • Drug Pipelines
  • 59 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • MallInckrodt Plc
  • Palatin Technologies Inc
  • SolaranRx Inc
  • SynAct Pharma AB
  • MORE
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H1 2018

Summary:

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH).

When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 5 respectively.

Report covers products from therapy areas Dermatology, Gastrointestinal, Musculoskeletal Disorders, Ophthalmology, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones and Oncology which include indications Inflammatory Bowel Disease, Vitiligo, Amyotrophic Lateral Sclerosis, Gouty Arthritis (Gout), Kidney Disease, Metastatic Melanoma, Ocular Inflammation, Peritonitis, Porphyria (Erythropoietic Protoporphyri), Psoriatic Arthritis, Ulcerative Colitis and Uveitis.

The latest report Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2018, outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • MallInckrodt Plc
  • Palatin Technologies Inc
  • SolaranRx Inc
  • SynAct Pharma AB
  • MORE
Introduction

Report Coverage

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development

Clinuvel Pharmaceuticals Ltd

MallInckrodt Plc

Palatin Technologies Inc

SolaranRx Inc

SynAct Pharma AB

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles

afamelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUV-9900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8331 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-1177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLRX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones

Featured News & Press Releases

Feb 05, 2018 : Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist

Jan 30, 2018 : First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis

Jan 03, 2018 : Palatin Technologies Announces FDA Clearance of Investigational New Drug Application for PL-8177 for Ulcerative Colitis

Dec 21, 2017: Preliminary recommendation by NICE not to include SCENESSE for reimbursement by NHS England

Dec 04, 2017: Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting

Oct 26, 2017: Mallinckrodt Presents Multiple Sclerosis Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017)

Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article

Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis

Sep 19, 2017: Clinuvel Provides Update on Scenesse FDA Filing

Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters

Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel Published in Advances in Therapy

Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov

Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert

Jun 22, 2017: Mallinckrodt Statement on H.P. Acthar Gel Update

Jun 14, 2017: Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2018

Pipeline by MallInckrodt Plc, H1 2018

Pipeline by Palatin Technologies Inc, H1 2018

Pipeline by SolaranRx Inc, H1 2018

Pipeline by SynAct Pharma AB, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Clinuvel Pharmaceuticals Ltd
  • MallInckrodt Plc
  • Palatin Technologies Inc
  • SolaranRx Inc
  • SynAct Pharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll